Supply of Menveo meningococcal conjugate vaccine by Novartis Vaccines and Diagnostics Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the importation, supply, and advertising of therapeutic goods in Australia. The Act was introduced to address the need for stringent control over the quality, safety, and efficacy of therapeutic goods to protect public health. Administered by the Parliament of the Commonwealth of Australia, the Act aims to ensure that therapeutic goods available in the Australian market are of acceptable quality and do not pose a risk to consumers. One specific instance of legislative action under this Act involved the Secretary of the Department of Health and Ageing granting consent on 19 December 2012 for the supply of MENVEO meningococcal conjugate vaccine by Novartis Vaccines and Diagnostics Pty Ltd. This consent included an exception from certain labelling requirements, demonstrating the flexibility of the Act to accommodate exceptional circumstances while maintaining its overarching policy objective of safeguarding public health.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation of therapeutic goods in Australia, encompassing a wide range of products from medicines and medical devices to blood and tissues. This Act governs the approval, advertising, and supply of these goods to ensure their safety, quality, and efficacy. The Act applies to entities and individuals involved in the manufacture, import, supply, or advertising of therapeutic goods within Australia, and it also regulates the conduct related to these activities. The scope of the Act extends nationally, as it is a Commonwealth Act, thereby ensuring uniform regulation across all states and territories. While the Act broadly applies to the therapeutic goods industry, there are specific exclusions and exemptions, such as certain over-the-counter medicines and devices that fall under lower-risk categories. The application of the Act may also be extended or restricted through subordinate instruments, such as regulations and orders, which provide detailed specifications and exceptions pertinent to particular types of therapeutic goods.

Key Provisions

The Therapeutic Goods Act 1989, in its sections 14 and 14A, provides mechanisms for granting consent to supply therapeutic goods under certain conditions. Specifically, on 19 December 2012, the delegate of the Secretary of the Department of Health and Ageing issued a consent (sections 14 and 14A) allowing Novartis Vaccines and Diagnostics Pty Ltd to supply the MENVEO meningococcal conjugate vaccine. Additionally, the consent permits this vaccine to be supplied with vial labels that do not conform to the requirements set out in clause 3(2)(b) and 3(2)(c) of Therapeutic Goods Order No 69. These clauses typically require the listing of the name and quantity of active ingredients on the labels. The obligations imposed by this consent on Novartis Vaccines and Diagnostics Pty Ltd include the adherence to the terms of the consent, which allows for the deviation from standard labelling requirements. This means the company must ensure that other information critical for the safe and effective use of the vaccine is still present and accurately conveyed on the labels. Furthermore, the company must comply with all other relevant requirements of the Therapeutic Goods Act 1989 and any associated regulations and orders. The Therapeutic Goods Act 1989 also outlines potential consequences for non-compliance with its provisions. Any breach of the Act or associated regulations can lead to both civil and criminal penalties. For civil penalties, the Act stipulates that an entity found in breach may be subject to fines. The maximum penalty for individuals is typically specified in the Act or related regulations, and for corporations, the maximum fines can be substantial, reflecting the seriousness of non-compliance in the therapeutic goods sector. Additionally, criminal sanctions may apply, which can include imprisonment for individuals responsible for the breach, further emphasising the importance of adhering to the legislative requirements.